Nicolas Gendron: Everolimus and Venous Thromboembolic Risk in Kidney Transplantation
Nicolas Gendron, Postdoctorate research Fellow at Harvard Medical School, Research Fellow and Hematologist at Boston Children’s Hospital, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Everolimus and venous thromboembolic risk in kidney transplantation
We are pleased to share with Lina Khider the results of our retrospective observational study, combining a case series and an analysis of the French National Pharmacovigilance Database.
Everolimus, a selective mTOR inhibitor widely used in transplantation, has already been associated with an increased risk of MVTE in heart and lung transplant recipients. Its impact on kidney transplant patients remained poorly documented.
Our main results:
In our center: 5 kidney transplant patients on everolimus presented with MVTE, including 3 recurrences. Median time to onset: 11 months after initiation.
16 additional cases identified via national pharmacovigilance, all organs combined (heart 43.8percent, lung 18.8percent, kidney 18.8percent)
The risk appears to be particularly marked in patients with a history of EVD before transplantation and during the first year after the introduction of everolimus.
Our observations suggest a link between everolimus and the risk of MVTE in renal transplant patients on everolimus, especially those with a personal history of EVD.
Further studies are needed to confirm these findings and guide clinical practice.”
Title: Venous Thromboembolism in Patients Treated with Everolimus: Insights from a Case Series and the French Pharmacovigilance Database
Authors: Audrey Delarue, Nicolas Gendron, Agnès Lillo-Le-Louet, Guillaume Goudot, Stephane Roueff, Helene Lazareth, Eric Thervet, Emmanuel Messas, Tristan Mirault, Lina Khider
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 9, 2026, 09:29Veronica Sanchez: A Framework for Woman’s Health
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause